The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.
about
The "dual-pathway" strategy after acute coronary syndrome: rivaroxaban and antiplatelet agents in the ATLAS ACS 2-TIMI 51 trial.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The "dual-pathway" strategy af ...... the ATLAS ACS 2-TIMI 51 trial.
@en
type
label
The "dual-pathway" strategy af ...... the ATLAS ACS 2-TIMI 51 trial.
@en
prefLabel
The "dual-pathway" strategy af ...... the ATLAS ACS 2-TIMI 51 trial.
@en
P2860
P356
P1476
The "dual-pathway" strategy af ...... the ATLAS ACS 2-TIMI 51 trial.
@en
P2093
Deepa Iyer
Marc Cohen
P2860
P304
P356
10.1111/1755-5922.12083
P577
2014-10-01T00:00:00Z